-
Product Insights
New![]()
Net Present Value Model: Annovis Bio Inc’s Buntanetap
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Synlogic Inc’s SYNB-1934
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.Drug Operating Profit Model
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ANVS-301 in Alzheimer’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ANVS-301 in Alzheimer's Disease Drug Details:ANVS-301 is under development for the treatment of cognitive capability in...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BD-111 in Simplexvirus (HSV) Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BD-111 in Simplexvirus (HSV) Infections Drug Details:BD-111 is under development for the treatment of viral keratitis...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VRVg-2 in Rabies
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.VRVg-2 in RabiesDrug Details:VRVg-2 is under development for the prevention of rabies. It is a purified...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Buntanetap Tartrate in Parkinson’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Buntanetap Tartrate in Parkinson's Disease Drug Details:Buntanetap (ANVS-401 (Posiphen)) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Buntanetap Tartrate in Frontotemporal Dementia (FTD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Buntanetap Tartrate in Frontotemporal Dementia (FTD)Drug Details:Buntanetap (ANVS-401 (Posiphen)) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Buntanetap Tartrate in Lewy Body Dementia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Buntanetap Tartrate in Lewy Body Dementia Drug Details: Buntanetap (ANVS-401 (Posiphen)) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NUC-7738 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NUC-7738 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drug Details: NUC-7738 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Exarafenib in Rectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Exarafenib in Rectal Cancer Drug Details: Exarafenib is under development for the treatment of solid tumors,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.